We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




D-Dimer Blood Test Detects Prosthetic Joint Infections as Accurately as Standard Tests

By LabMedica International staff writers
Posted on 13 Feb 2023
Print article
Image: D-dimer can help in making the difficult diagnosis of prosthetic joint infection (Photo courtesy of Pexels)
Image: D-dimer can help in making the difficult diagnosis of prosthetic joint infection (Photo courtesy of Pexels)

Periprosthetic joint infection (PJI) is a serious complication of failed total hip or knee replacement and among the primary causes of implant failure. Diagnosing PJI can be highly challenging because there is no single test that can claim to have 100% accuracy in determining or ruling out its presence. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), which are two common markers of inflammation, are recommended as screening tests for patients suspected of having PJI. However, both these markers have limitations, such as a high rate of false-negative results when PJI is present. Plasma D-dimer, a test commonly used for certain blood clot-related disorders, is also a potentially useful marker of infection and has been validated for use in the diagnosis of PJI. However, some studies have raised concerns over the diagnostic performance of D-dimer testing for PJI, and its true accuracy is still unknown. Now, a new study suggests that the measurement of plasma D-dimer levels can provide useful information when making the difficult diagnosis of PJI.

In the new study, researchers at Thomas Jefferson University (Philadelphia, PA, USA) compared plasma D-dimer and other tests for the diagnosis of PJI. Over a four-year period, the study prospectively enrolled 502 patients undergoing revision knee or hip arthroplasty, irrespective of their surgical indication. All the patients underwent a blood draw just before their surgery to measure their levels of D-dimer, CRP, and ESR, and fibrinogen. After applying the 2018 International Consensus Meeting definition of PJI, the researchers found 23% of the patients had PJI. The four tests had "comparable accuracy" for the diagnosis of PJI. Sensitivity (ability to detect PJI when present) was 81.3% for D-dimer, 90.4% for CRP, 73.9% for ESR, and 74.7% for fibrinogen. On the other hand, specificity (correctly showing that PJI was not present) was 81.7% for D-dimer, 70.0% for CRP, 85.2% for ESR, and 75.4% for fibrinogen. For all four measures, the values were higher for patients who were shown to have PJI.

However, in some patient subgroups, D-dimer offered a diagnostic advantage. In a sub-analysis that excluded patients with certain health conditions associated with inflammation, the D-dimer test outperformed ESR, fibrinogen, and CRP in recognizing the presence of PJI. D-dimer also performed best in detecting PJI caused by slow-growing "indolent" organisms, with higher values for both sensitivity and specificity. Additionally, all the four tests showed a better diagnostic performance in patients with suspected PJI in the knee, as compared with PJI in the hip. The report is the largest prospective study evaluating the performance of different laboratory tests for suspected PJI and support D-dimer testing as a valuable tool for the often-difficult diagnosis of PJI. There is a need for further studies, and no universal diagnostic cutoff point can be determined due to known variations in D-dimer measurement, according to the researchers.

"We found that plasma D-dimer was noninferior to serum CRP and ESR in the diagnosis of PJI and may be a useful adjunct when screening patients undergoing revision total joint arthroplasty," said Javad Parvizi, MD, FRCS, and colleagues of Rothman Orthopedic Institute at Thomas Jefferson University.

Related Links:
Thomas Jefferson University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Benchtop Cooler
PCR-Cooler & PCR-Rack
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.